 | • レポートコード：MRC2307A0043 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、196ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当市場調査書によると、世界のカテコールアミン市場規模が、2023年の40億ドルから2031年までに67億ドルに達し、予測期間中にCAGR（年平均成長率）5.9%で拡大すると予想されています。本書は、カテコールアミンの世界市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（内因性、合成）分析、投与経路別（静脈、吸入、経皮、その他）分析、疾患別（アナフィラキシー、心停止、急性喘息、ショック、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。なお、Pfizer, Inc.,、Baxter International、Novartis International AG (Sandoz)、Breckenridge Pharmaceutical, Inc.、Viatris, Inc. (Mylan N.V)、Mallinckrodt Pharmaceuticals、Amneal Pharmaceuticals、Lexicare Pharma Pvt. Ltd.、Midas Pharma GmbH、Armstrong Pharmaceuticals, Inc.、Adamis Pharmaceuticals Corporation、Teva Pharmaceutical Industries Ltd.など、主要企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界のカテコールアミン市場規模：薬剤別 - 内因性カテコールアミンの市場規模 - 合成カテコールアミンの市場規模 ・世界のカテコールアミン市場規模：投与経路別 - 静脈投与における市場規模 - 吸入投与における市場規模 - 経皮投与における市場規模 - その他投与経路における市場規模 ・世界のカテコールアミン市場規模：疾患別 - アナフィラキシーにおける市場規模 - 心停止における市場規模 - 急性喘息における市場規模 - ショックにおける市場規模 - その他疾患における市場規模 ・世界のカテコールアミン市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のカテコールアミン市場規模：地域別 - 北米のカテコールアミン市場規模 - ヨーロッパのカテコールアミン市場規模 - アジア太平洋のカテコールアミン市場規模 - 中南米のカテコールアミン市場規模 - 中東・アフリカのカテコールアミン市場規模 ・競争状況 |
Catecholamines Market – Scope of Report
TMR’s report on the global Catecholamines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Catecholamines market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Catecholamines market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Catecholamines market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Catecholamines market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Catecholamines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Catecholamines market.
The report delves into the competitive landscape of the global Catecholamines market. Key players operating in the global Catecholamines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Catecholamines market profiled in this report.
Key Questions Answered in Global Catecholamines Market Report
• What is the sales/revenue generated by Catecholamines across all regions during the forecast period?
• What are the opportunities in the global Catecholamines market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Catecholamines Market – Research Objectives and Research Approach
The comprehensive report on the global Catecholamines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Catecholamines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Catecholamines market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Catecholamines Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Catecholamines Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Overview of Catecholamines Market
5.2. Regulatory Scenario Globally/Region
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry
6. Global Catecholamines Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017-2031
6.3.1. Endogenous
6.3.2. Synthetic
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Catecholamines Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Intravenous
7.3.2. Inhalation
7.3.3. Transdermal
7.3.4. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Catecholamines Market Analysis and Forecasts, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017-2031
8.3.1. Anaphylaxis
8.3.2. Cardiac Arrest
8.3.3. Acute Asthma
8.3.4. Shock
8.3.5. Hypertension
8.3.6. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Catecholamines Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Catecholamines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, By Region
11. North America Catecholamines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017-2031
11.2.1. Endogenous
11.2.2. Synthetic
11.3. Market Value Forecast, by Route of Administration, 2017-2031
11.3.1. Intravenous
11.3.2. Inhalation
11.3.3. Transdermal
11.3.4. Others
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Anaphylaxis
11.4.2. Cardiac Arrest
11.4.3. Acute Asthma
11.4.4. Shock
11.4.5. Hypertension
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Catecholamines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017-2031
12.2.1. Endogenous
12.2.2. Synthetic
12.3. Market Value Forecast, by Route of Administration, 2017-2031
12.3.1. Intravenous
12.3.2. Inhalation
12.3.3. Transdermal
12.3.4. Others
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Anaphylaxis
12.4.2. Cardiac Arrest
12.4.3. Acute Asthma
12.4.4. Shock
12.4.5. Hypertension
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Catecholamines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017-2031
13.2.1. Endogenous
13.2.2. Synthetic
13.3. Market Value Forecast, by Route of Administration, 2017-2031
13.3.1. Intravenous
13.3.2. Inhalation
13.3.3. Transdermal
13.3.4. Others
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Anaphylaxis
13.4.2. Cardiac Arrest
13.4.3. Acute Asthma
13.4.4. Shock
13.4.5. Hypertension
13.4.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Catecholamines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017-2031
14.2.1. Endogenous
14.2.2. Synthetic
14.3. Market Value Forecast, by Route of Administration, 2017-2031
14.3.1. Intravenous
14.3.2. Inhalation
14.3.3. Transdermal
14.3.4. Others
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Anaphylaxis
14.4.2. Cardiac Arrest
14.4.3. Acute Asthma
14.4.4. Shock
14.4.5. Hypertension
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Catecholamines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017-2031
15.2.1. Endogenous
15.2.2. Synthetic
15.3. Market Value Forecast, by Route of Administration, 2017-2031
15.3.1. Intravenous
15.3.2. Inhalation
15.3.3. Transdermal
15.3.4. Others
15.4. Market Value Forecast, by Indication, 2017-2031
15.4.1. Anaphylaxis
15.4.2. Cardiac Arrest
15.4.3. Acute Asthma
15.4.4. Shock
15.4.5. Hypertension
15.4.6. Others
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Pfizer, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Baxter International
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Novartis International AG (Sandoz)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Breckenridge Pharmaceutical, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Viatris, Inc. (Mylan N.V)
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Mallinckrodt Pharmaceuticals
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Amneal Pharmaceuticals.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Lexicare Pharma Pvt. Ltd.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Midas Pharma GmbH
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Armstrong Pharmaceuticals, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Adamis Pharmaceuticals Corporation
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Teva Pharmaceutical Industries Ltd.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
Table 01: Global Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 02: Global Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 03: Global Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 04: Global Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Catecholamines Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Catecholamines Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 08: North America Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 09: North America Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 10: North America Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 13: Europe Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 14: Europe Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: Europe Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 18: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 19: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Asia Pacific Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 23: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 24: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 25: Latin America Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 28: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 29: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Middle East & Africa Catecholamines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031